Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data Provided by Dow Jones Jun 4, 2024, 12:10:00 AM. By Josh Beckerman .

The Food and Drug Administration has flagged Guillain-Barre syndrome, a rare neurological condition, as a potential risk for Pfizer’s respiratory syncytial virus (RSV) vaccine. Two people in … ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Guillain-Barre Syndrome (GBS) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This comprehensive analysis of ...

The Food and Drug Administration (FDA) has granted Fast Track designation to ANX005 (Annexon Biosciences) for the treatment of Guillain-Barré Syndrome (GBS), an autoimmune disease that can lead ...

Annexon announces positive topline results from pivotal phase 3 trial for first-in-class C1q blocking antibody ANX005 in Guillain-Barré syndrome. News release. Annexon, Inc. June 4, 2024.

(RTTNews) - Annexon, Inc. (ANNX) announced the European Medicines Agency granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome. Advantages of the orphan drug ...

Johnson & Johnson’s beleaguered Covid-19 vaccine may be associated with a small increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition, federal ...

In extremely rare cases, Guillain-Barré Syndrome can occur after a vaccination, the Centers for Disease Control says, and there was some initial concern from Americans that the COVID-19 vaccines ...

Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data. Last Updated: June 3, 2024 at 8:10 p.m. ET First Published: June 3, 2024 at 6:44 p.m. ET. Share.